Simon L Goodman

List of Publications by Year
in descending order

61 papers	10,054 citations	71004 43 h-index	124990 64 g-index
65 all docs	65 docs citations	65 times ranked	11074 citing authors

#	Article	IF	Citations
1	The Antibody Societyâ€™s antibody validation webinar series. MAbs, 2020, 12, 1794421.	2.6	26
2	The antibody horror show: an introductory guide for the perplexed. New Biotechnology, 2018, 45, 9-13.	2.4	34
3	The path to VICTORy â€“ a beginner's guide to success using commercial research antibodies. Journal of Cell Science, 2018, 131, .	1.2	10
4	Integrins as Therapeutic Targets: Successes and Cancers. Cancers, 2017, 9, 110.	1.7	177
5	Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome. Oncotarget, 2016, 7, 15018-15032.	0.8	62
6	Integrins Î±vÎ²3 and Î±vÎ²5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer, 2015, 18, 784-795.	2.7	50
7	Structural basis for pure antagonism of integrin Î±VÎ²3 by a high-affinity form of fibronectin. Nature Structural and Molecular Biology, 2014, 21, 383-388.	3.6	104
8	Integrins and their ligands are expressed in non-small cell lung cancer but not correlated with parameters of disease progression. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 69-78.	1.4	25
9	Atomic Basis for the Species-specific Inhibition of Î±V Integrins by Monoclonal Antibody 17E6 Is Revealed by the Crystal Structure of Î±VÎ²3 Ectodomain-17E6 Fab Complex. Journal of Biological Chemistry, 2014, 289, 13801-13809.	1.6	32
10	Î±vÎ²3, Î±vÎ²5 and Î±vÎ²6 integrins in brain metastases of lung cancer. Clinical and Experimental Metastasis, 2014, 31, 841-851.	1.7	51
11	Invasion patterns in brain metastases of solid cancers. Neuro-Oncology, 2013, 15, 1664-1672.	0.6	191
12	Integrin control of the transforming growth factor-Î² pathway in glioblastoma. Brain, 2013, 136, 564-576.	3.7	94
13	The Î±VÎ²3/Î±VÎ²5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model. International Journal of Cancer, 2013, 132, 2694-2704.	2.3	9
14	Longitudinal Expression Analysis of Î±v Integrins in Human Gliomas Reveals Upregulation of Integrin Î±vÎ²3 as a Negative Prognostic Factor. Journal of Neuropathology and Experimental Neurology, 2013, 72, 194-210.	0.9	46
15	Validation and Comparison of Anti-Î±vÎ²3 and Anti-Î±vÎ²5 Rabbit Monoclonal Versus Murine Monoclonal Antibodies in Four Different Tumor Entities. Applied Immunohistochemistry and Molecular Morphology, 2013, 21, 553-560.	0.6	9
16	Î±vâ€‰integrin isoform expression in primary human tumors and brain metastases. International Journal of Cancer, 2013, 133, 2362-2371.	2.3	94
17	Comparing the expression of integrins Î±vÎ²3, Î±vÎ²5, Î±vÎ²6, Î±vÎ²8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. International Journal of Clinical and Experimental Pathology, 2013, 6, 2719-32.	0.5	29
18	Matched rabbit monoclonal antibodies against Î±v-series integrins reveal a novel Î±vÎ²3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biology Open, 2012, 1, 329-340.	0.6	70

#	Article	IF	Citations
19	Integrins as therapeutic targets. Trends in Pharmacological Sciences, 2012, 33, 405-412.	4.0	340
20	Immunohistochemical analysis of integrins Î±vÎ²3, Î±vÎ²5 and Î±5Î²1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Experimental and Therapeutic Medicine, 2011, 2, 9-19.	0.8	42
21	Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCEâ€MRI in a longitudinal in vivo study. International Journal of Cancer, 2011, 128, 2453-2462.	2.3	78
22	Pharmacological inhibition of integrin Î±vÎ²3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology, 2009, 50, 1501-1511.	3.6	154
23	Radiation sensitization of glioblastoma by cilengitide has unanticipated scheduleâ€dependency. International Journal of Cancer, 2009, 124, 2719-2727.	2.3	120
24	Crystal structure of the complete integrin Î±VÎ²3 ectodomain plus an Î±/Î² transmembrane fragment. Journal of Cell Biology, 2009, 186, 589-600.	2.3	163
25	Circulating and imaging markers for angiogenesis. Angiogenesis, 2008, 11, 321-335.	3.7	40
26	Inhibition of Integrin Î±vÎ²6 on Cholangiocytes Blocks Transforming Growth Factor-Î² Activation and Retards Biliary Fibrosis Progression. Gastroenterology, 2008, 135, 660-670.	0.6	177
27	CYR61 and Î±VÎ²5 Integrin Cooperate to Promote Invasion and Metastasis of Tumors Growing in Preirradiated Stroma. Cancer Research, 2008, 68, 7323-7331.	0.4	109
28	Pharmacological inhibition of the vitronectin receptor abrogates PDGF-BB-induced hepatic stellate cell migration and activation in vitro. Journal of Hepatology, 2007, 46, 878-887.	1.8	56
29	Purification, Analysis, and Crystal Structure of Integrins. Methods in Enzymology, 2007, 426, 307-336.	0.4	16
30	Structure and mechanics of integrin-based cell adhesion. Current Opinion in Cell Biology, 2007, 19, 495-507.	2.6	368
31	Piltdown wasn't cricket but does the hobbit ring true?. Nature, 2006, 443, 394-394.	13.7	1
32	Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy. International Journal of Cancer, 2006, 118, 755-764.	2.3	30
33	Titanium Implant Materials with Improved Biocompatibility through Coating with Phosphonate-Anchored Cyclic RGD Peptides. ChemBioChem, 2005, 6, 2034-2040.	1.3	103
34	Dissecting the Role of Matrix Metalloproteinases (MMP) and Integrin Î±vÎ²3 in Angiogenesis In vitro: Absence of Hemopexin C Domain Bioactivity, but Membrane-Type 1-MMP and Î±vÎ²3 Are Critical. Cancer Research, 2005, 65, 9377-9387.	0.4	65
35	Three-dimensional EM structure of the ectodomain of integrin Î±VÎ²3 in a complex with fibronectin. Journal of Cell Biology, 2005, 168, 1109-1118.	2.3	166
36	A Novel Adaptation of the Integrin PSI Domain Revealed from Its Crystal Structure. Journal of Biological Chemistry, 2004, 279, 40252-40254.	1.6	84

#	Article	IF	Citations
37	Improving Implant Materials by Coating with Nonpeptidic, Highly Specific Integrin Ligands. Angewandte Chemie - International Edition, 2004, 43, 6649-6652.	7.2	39
38	ÂvÂ3 and Î±vÎ²5 integrin antagonists inhibit angiogenesis in vitro. Angiogenesis, 2003, 6, 105-119.	3.7	183
39	Multimeric Cyclic RGD Peptides as Potential Tools for Tumor Targeting: Solid-Phase Peptide Synthesis and Chemoselective Oxime Ligation. Chemistry - A European Journal, 2003, 9, 2717-2725.	1.7	252
40	Integrins, cations and ligands: making the connection. Journal of Thrombosis and Haemostasis, 2003, 1, 1642-1654.	1.9	71
41	New insights into the structural basis of integrin activation. Blood, 2003, 102, 1155-1159.	0.6	170
42	Nanomolar Small Molecule Inhibitors for Î±vÎ²6, Î±vÎ²5, and Î±vÎ²3 Integrins. Journal of Medicinal Chemistry, 2002, 45, 1045-1051.	2.9	183
43	Divalent cations and the relationship between Î±A and Î²A domains in integrins. Biochemical Pharmacology, 2002, 64, 805-812.	2.0	4
44	Coming to grips with integrin binding to ligands. Current Opinion in Cell Biology, 2002, 14, 641-652.	2.6	172
45	Crystal Structure of the Extracellular Segment of Integrin alpha Vbeta 3 in Complex with an Arg-Gly-Asp Ligand. Science, 2002, 296, 151-155.	6.0	1,529
46	Solid-Phase Synthesis of a Nonpeptide RGD Mimetic Library:â€‰ New Selective Î±vÎ²3 Integrin Antagonists. Journal of Medicinal Chemistry, 2001, 44, 1938-1950.	2.9	105
47	Nonpeptidic Î±vÎ²3 Integrin Antagonist Libraries: On-Bead Screening and Mass Spectrometric Identification without Tagging. Angewandte Chemie - International Edition, 2001, 40, 165-169.	7.2	33
48	Crystal Structure of the Extracellular Segment of Integrin alpha Vbeta 3. Science, 2001, 294, 339-345.	6.0	1,202
49	Carbohydrate Derivatives for Use in Drug Design: CyclicÎ±v-Selective RGD Peptides. Angewandte Chemie - International Edition, 2000, 39, 2761-2764.	7.2	120
50	Surface Coating with Cyclic RGD Peptides Stimulates Osteoblast Adhesion and Proliferation as well as Bone Formation. ChemBioChem, 2000, 1, 107-114.	1.3	285
51	Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2000, 15, 71-79.	0.7	42
52	Definition of an Unexpected Ligand Recognition Motif for Î±vÎ²6 Integrin. Journal of Biological Chemistry, 1999, 274, 1979-1985.	1.6	126
53	N-Methylated Cyclic RGD Peptides as Highly Active and Selective Î±VÎ²3 Integrin Antagonists. Journal of Medicinal Chemistry, 1999, 42, 3033-3040.	2.9	788
54	Novel Solid-Phase Synthesis of Azapeptides and Azapeptoides via Fmoc-Strategy and Its Application in the Synthesis of RGD-Mimetics. Journal of Organic Chemistry, 1999, 64, 7388-7394.	1.7	82

#	Article	IF	Citations
55	Decreased angiogenesis and arthritic disease in rabbits treated with an Î±vÎ²3 antagonist. Journal of Clinical Investigation, 1999, 103, 47-54.	3.9	285
56	Immunohistochemical analysis of integrin Î±vÎ²3 expression on tumor-associated vessels of human carcinomas. , 1997, 71, 320-324.		151
57	Cyclic RGD Peptides Containing Î²-Turn Mimetics. Journal of the American Chemical Society, 1996, 118, 7881-7891.	6.6	140
58	Structural and Functional Aspects of RGD-Containing Cyclic Pentapeptides as Highly Potent and Selective Integrin Î±VÎ²3Antagonists. Journal of the American Chemical Society, 1996, 118, 7461-7472.	6.6	581
59	Design of superactive and selective integrin receptor antagonists containing the RGD sequence. International Journal of Peptide Research and Therapeutics, 1995, 2, 155-160.	0.1	57
60	Control of cell locomotion: perturbation with an antibody directed against specific glycoproteins. Cell, 1985, 41, 1029-1038.	13.5	51
61	Cell-cell interaction and polarity of epithelial cells: Specific perturbation using a monoclonal antibody. Cell, 1983, 35, 667-675.	13.5	147